NewGenIvf Ebitda from 2010 to 2024

NIVF Stock   0.39  0.02  4.88%   
NewGenIvf Group's EBITDA is decreasing over the last several years with slightly volatile swings. EBITDA is estimated to finish at about -2.4 M this year. During the period from 2010 to 2024 NewGenIvf Group Limited EBITDA regressed destribution of quarterly values had mean deviationof  766,194 and mean square error of 698.7 B. View All Fundamentals
 
EBITDA  
First Reported
2010-12-31
Previous Quarter
-2.5 M
Current Value
-2.4 M
Quarterly Volatility
1.1 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check NewGenIvf Group financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NewGenIvf Group's main balance sheet or income statement drivers, such as Tax Provision of 0.0, Interest Income of 544 or Depreciation And Amortization of 233.7 K, as well as many indicators such as Price To Sales Ratio of 17.99, Dividend Yield of 0.0 or PTB Ratio of 3.99. NewGenIvf financial statements analysis is a perfect complement when working with NewGenIvf Group Valuation or Volatility modules.
  
Check out the analysis of NewGenIvf Group Correlation against competitors.

Latest NewGenIvf Group's Ebitda Growth Pattern

Below is the plot of the Ebitda of NewGenIvf Group Limited over the last few years. It is NewGenIvf Group's EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NewGenIvf Group's overall financial position and show how it may be relating to other accounts over time.
Ebitda10 Years Trend
Slightly volatile
   Ebitda   
       Timeline  

NewGenIvf Ebitda Regression Statistics

Arithmetic Mean108,141
Coefficient Of Variation998.14
Mean Deviation766,194
Median587,012
Standard Deviation1,079,401
Sample Variance1.2T
Range3.1M
R-Value(0.67)
Mean Square Error698.7B
R-Squared0.44
Significance0.01
Slope(160,675)
Total Sum of Squares16.3T

NewGenIvf Ebitda History

2024-2.4 M
2023-2.5 M
2022-504.9 K

About NewGenIvf Group Financial Statements

NewGenIvf Group stakeholders use historical fundamental indicators, such as NewGenIvf Group's Ebitda, to determine how well the company is positioned to perform in the future. Although NewGenIvf Group investors may analyze each financial statement separately, they are all interrelated. For example, changes in NewGenIvf Group's assets and liabilities are reflected in the revenues and expenses on NewGenIvf Group's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in NewGenIvf Group Limited. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EBITDA-2.5 M-2.4 M

Currently Active Assets on Macroaxis

When determining whether NewGenIvf Group is a strong investment it is important to analyze NewGenIvf Group's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact NewGenIvf Group's future performance. For an informed investment choice regarding NewGenIvf Stock, refer to the following important reports:
Check out the analysis of NewGenIvf Group Correlation against competitors.
You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NewGenIvf Group. If investors know NewGenIvf will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NewGenIvf Group listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of NewGenIvf Group is measured differently than its book value, which is the value of NewGenIvf that is recorded on the company's balance sheet. Investors also form their own opinion of NewGenIvf Group's value that differs from its market value or its book value, called intrinsic value, which is NewGenIvf Group's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NewGenIvf Group's market value can be influenced by many factors that don't directly affect NewGenIvf Group's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NewGenIvf Group's value and its price as these two are different measures arrived at by different means. Investors typically determine if NewGenIvf Group is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NewGenIvf Group's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.